📄️ Bridge Thesis
The proposition
📄️ Path to €1M ARR
The bridge round funds the acceleration from our Budget trajectory (conservative, organic) to our Model trajectory (€1M ARR EoY 2026). Both scenarios are derived from internal financial planning. The gap between them is what the bridge capital activates.
📄️ Use of Funds
Allocation of the €1.5M-€2.0M bridge round. Every euro is tied to a measurable outcome that contributes to the path from €300K to €1M ARR by EoY 2026.
📄️ Value Creation Since Seed
In the 16 months since closing the seed round (Q4 2024), Legit.Health has built the platform required for accelerated growth: a commercial team, new tier-1 customer logos, additional regulatory certifications, scientific output, captured grants, and operational maturity. Top-line revenue undershot the optimistic 2024 budget, but every foundational asset that drives the next phase is now in place.